| dbo:abstract |
Mozavaptan (INN) is a vasopressin receptor antagonist marketed by Otsuka. In Japan, it was approved in October 2006 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH) due to ADH producing tumors. (en) モザバプタン（Mozavaptan）バソプレシン受容体阻害薬である。商品名フィズリン。1989年に大塚製薬が創薬した。2001年に希少疾病用医薬品に指定され、2006年7月に承認された。 (ja) |
| dbo:casNumber |
137975-06-5 |
| dbo:chEMBL |
420762 |
| dbo:fdaUniiCode |
17OJ42922Y |
| dbo:pubchem |
119369 |
| dbo:thumbnail |
wiki-commons:Special:FilePath/Mozavaptan_structure.svg?width=300 |
| dbo:wikiPageExternalLink |
http://www.prous.com/molecules/default.asp%3FID=153 https://web.archive.org/web/20120213003638/http:/www.prous.com/molecules/default.asp%3FID=153%7Carchive-date |
| dbo:wikiPageID |
18594493 (xsd:integer) |
| dbo:wikiPageLength |
2910 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1120071879 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbc:Benzanilides dbr:Vasopressin_receptor_antagonist dbr:Hyponatremia dbc:Diuretics dbc:Benzazepines dbc:2-Tolyl_compounds dbr:International_Nonproprietary_Name dbc:Vasopressin_receptor_antagonists dbr:Sodium dbr:Otsuka_Pharmaceutical_Co. dbr:Syndrome_of_inappropriate_antidiuretic_hormone |
| dbp:atcPrefix |
none (en) |
| dbp:c |
27 (xsd:integer) |
| dbp:casNumber |
137975 (xsd:integer) |
| dbp:chembl |
420762 (xsd:integer) |
| dbp:chemspiderid |
106618 (xsd:integer) |
| dbp:h |
29 (xsd:integer) |
| dbp:iupacName |
N-[4-phenyl]-2-methylbenzamide (en) |
| dbp:iupharLigand |
2197 (xsd:integer) |
| dbp:legalStatus |
Rx-only (en) |
| dbp:n |
3 (xsd:integer) |
| dbp:o |
2 (xsd:integer) |
| dbp:pubchem |
119369 (xsd:integer) |
| dbp:routesOfAdministration |
Oral (en) |
| dbp:smiles |
Cc1ccccc1CNc2cccCN3c4ccccc4CNC (en) |
| dbp:stdinchi |
1 (xsd:integer) |
| dbp:stdinchikey |
WRNXUQJJCIZICJ-UHFFFAOYSA-N (en) |
| dbp:unii |
17 (xsd:integer) |
| dbp:verifiedfields |
changed (en) |
| dbp:verifiedrevid |
462255885 (xsd:integer) |
| dbp:wikiPageUsesTemplate |
dbt:Diuretics dbt:Antihypertensive-stub dbt:Cite_journal dbt:Cite_web dbt:Drugbox dbt:Short_description dbt:Cascite dbt:Chemspidercite dbt:Drugbankcite dbt:Ebicite dbt:Fdacite dbt:Stdinchicite dbt:Oxytocin_and_vasopressin_receptor_modulators |
| dcterms:subject |
dbc:Benzanilides dbc:Diuretics dbc:Benzazepines dbc:2-Tolyl_compounds dbc:Vasopressin_receptor_antagonists |
| gold:hypernym |
dbr:Antagonist |
| rdf:type |
owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 yago:Agent109190918 yago:Agent114778436 yago:CausalAgent100007347 yago:DiureticDrug103214670 yago:Drug103247620 yago:Matter100020827 yago:PhysicalEntity100001930 yago:WikicatHormonalAgents dbo:Drug yago:Substance100020090 yago:WikicatDiuretics umbel-rc:DrugProduct |
| rdfs:comment |
Mozavaptan (INN) is a vasopressin receptor antagonist marketed by Otsuka. In Japan, it was approved in October 2006 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH) due to ADH producing tumors. (en) モザバプタン（Mozavaptan）バソプレシン受容体阻害薬である。商品名フィズリン。1989年に大塚製薬が創薬した。2001年に希少疾病用医薬品に指定され、2006年7月に承認された。 (ja) |
| rdfs:label |
Mozavaptan (en) モザバプタン (ja) |
| owl:sameAs |
freebase:Mozavaptan yago-res:Mozavaptan wikidata:Mozavaptan dbpedia-fa:Mozavaptan dbpedia-ja:Mozavaptan dbpedia-sh:Mozavaptan dbpedia-sr:Mozavaptan dbpedia-vi:Mozavaptan https://global.dbpedia.org/id/JKdT |
| prov:wasDerivedFrom |
wikipedia-en:Mozavaptan?oldid=1120071879&ns=0 |
| foaf:depiction |
wiki-commons:Special:FilePath/Mozavaptan_structure.svg |
| foaf:isPrimaryTopicOf |
wikipedia-en:Mozavaptan |
| is dbo:wikiPageRedirects of |
dbr:C27H29N3O2 |
| is dbo:wikiPageWikiLink of |
dbr:Vasopressin_receptor_antagonist dbr:Aquaretic dbr:C27H29N3O2 dbr:Vasopressin_receptor dbr:Vasopressin_receptor_2 dbr:List_of_drugs:_Mo |
| is foaf:primaryTopic of |
wikipedia-en:Mozavaptan |
